Research programme: voltage-gated potassium channels - Cardiome

Drug Profile

Research programme: voltage-gated potassium channels - Cardiome

Alternative Names: Kv 1.5 channel blockers - Cardiome; Voltage-gated potassium channels research programme - Cardiome

Latest Information Update: 14 Sep 2004

Price : $50

At a glance

  • Originator Cardiome Pharma
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 14 Sep 2004 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)
  • 26 Sep 2001 This programme is available for licensing (
  • 27 Jun 2001 Nortran Pharmaceuticals is now called Cardiome Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top